经导管主动脉瓣植入术后肺动脉高压新定义与结局
本研究纳入579例接受TAVI并术前右心导管评估的患者,按新ESC标准分组。新标准使PH诊断率从32%升至52%,PH尤其伴PVR升高者术后死亡和心衰住院风险更高,仅I-PoC组术后mPAP正常化与生存改善相关。
要点
- 新ESC标准使TAVI患者PH诊断率从32%增至52%。
- PH伴PVR升高者术后死亡和心衰住院风险更高。
- 仅I-PoC组术后mPAP正常化与长期生存改善相关。
核心结论
- 新ESC PH标准增加PH诊断数量,PH尤其伴PVR升高者识别TAVI术后死亡和再住院高风险患者。
- 术后PH正常化仅与I-PoC组长期生存改善相关。
研究设计与样本
- 纳入579例连续接受TAVI且术前右心导管评估的患者,按无PH、I-PreC/Co PH和I-PoC PH分组。
- 中位随访2.9年,评估全因死亡、心血管死亡和心衰住院,并分析术后残余PH的预后作用。
主要发现
- 新标准诊断PH 299例(52%),旧标准诊断185例(32%)。
- 中位年龄82岁,男性55.3%,PH患者更常合并COPD和房颤且外科风险更高。
- 旧定义PH与更差生存(p<0.001)和心衰住院(p=0.002)相关,不论PVR值。
- 新切点下PH仅于PVR升高患者与更差结局相关,PH而PVR正常者与无PH者无差异。
- 术后mPAP正常化见于45%病例,但仅I-PoC组与长期生存改善相关。
关键数值与推荐
- 新ESC标准:mPAP>20 mmHg(旧为>25 mmHg)和PVR>2 Wood单位(旧为>3 Wood单位)。
临床怎么用
- TAVI术前右心导管评估可依据新ESC标准识别PH,尤其关注PVR升高者以评估术后风险。
- 术后mPAP正常化在I-PoC PH组提示生存改善,其他组别意义有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The European Society of Cardiology guidelines have recently defined new cut-offs for pulmonary hypertension (PH) and pulmonary vasculature resistance (PVR; median pulmonary artery pressure (mPAP) >20 instead of 25 mm Hg and PVR >2 instead of 3 Wood unit). The prognostic value of this updated classification after transcatheter aortic valve implantation (TAVI) is unknown. METHODS: 579 consecutive patients treated by TAVI with preprocedural right heart catheterisation evaluation were included. Patients were grouped as: (1) no PH, (2) isolated precapillary/combined (I-PreC/Co) PH and (3) isolated postcapillary PH (I-PoC). All-cause death, cardiovascular death and hospitalisations for heart failure (HF) were evaluated at follow-up. We also analysed the prognostic role of residual postprocedural PH. RESULTS: Out of 579 patients, 299 (52%) had PH according to the new criteria compared with 185 (32%) according to the previous ones. Overall median age was 82 years, while 55.3% patients were male. Patients with PH were more frequently diagnosed with chronic obstructive pulmonary disease and atrial fibrillation and were characterised by higher surgical risk as compared with patients without PH.At a median follow-up of 2.9 years, the presence of PH according to previous definition was associated with worse survival (p<0.001) and HF hospitalisation (p=0.002) rates, irrespective of PVR values. With newer cut-offs, PH was associated with worse outcomes only in patients with increased PVR, while no differences were found between patients with PH and normal PVR values and those without PH. Postprocedural mPAP normalisation was observed in 45% of the cases, but it was associated with improved long-term survival only in the I-PoC PH group. CONCLUSIONS: New ESC PH cut-offs increased the number of PH diagnoses. The presence of PH, particularly in the setting of increased PVR, identify patients at higher risk for postprocedural mortality and rehospitalisation. Normalisation of PH was associated with better survival only in I-PoC group.
引用
- Cardaioli F, Nai Fovino L, Fabris T, et al. Updated definition of pulmonary hypertension and outcome after transcatheter aortic valve implantation. Heart. 2023. PMID: 37414524. doi:10.1136/heartjnl-2023-322881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。